MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

14.19 +0.05 (+0.35%)
Official Closing Price Updated: 7:00 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 816,270
Open 14.13
Bid (Size) 13.90 (1,000)
Ask (Size) 14.25 (100)
Prev. Close 14.14
Today's Range 14.10 - 14.21
52wk Range 12.26 - 16.17
Shares Outstanding 166,301,231
Dividend Yield 0.64%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
From Aurigene Oncology Limited
Via Business Wire
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Fits the Peter Lynch Investment Strategy ↗
Dr. Reddy's Labs fits the Peter Lynch investment model with strong EPS growth, a low PEG ratio, minimal debt, and high ROE, making it a compelling GARP stock. 
Via Chartmill

Performance

YTD
-9.4%
-9.4%
1 Month
+5.9%
+5.9%
3 Month
-1.0%
-1.0%
6 Month
-8.7%
-8.7%
1 Year
-1.9%
-1.9%

More News

Read More
News headline image
Dr. Reddy's Laboratories (NYSE:RDY) Fits the Peter Lynch Investment Strategy ↗
Via Chartmill
News headline image
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025
From Aurigene Oncology Limited
Via Business Wire
News headline image
Dr. Reddy's Laboratories-ADR (NYSE:RDY) Meets Key Peter Lynch Investment Criteria ↗
Via Chartmill
News headline image
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs ↗
Via Benzinga
Topics Government World Trade
News headline image
Dr. Reddy's Laboratories-ADR (NYSE:RDY) Fits the Peter Lynch GARP Strategy ↗
Via Chartmill
News headline image
Dr. Reddy's Laboratories (NYSE:RDY): A Peter Lynch-Style GARP Investment ↗
Via Chartmill
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Fits Peter Lynch's Growth at a Reasonable Price (GARP) Strategy ↗
Via Chartmill
News headline image
Dr. Reddy’s Reports Record Revenues in Q1, Signals Steady Execution Through Transition Year
Via AB Newswire
Topics Earnings
News headline image
Dr. Reddy’s Q1FY26 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) – A GARP Candidate Worth Watching ↗
Via Chartmill
Expanding the Preventive Care Frontier: Dr. Reddy’s Launches Sanofi’s Beyfortus® in India
Via AB Newswire
Topics Death
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate in Pharmaceuticals ↗
Via Chartmill
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate Worth Considering ↗
Via Chartmill
News headline image
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug ↗
Via Benzinga
News headline image
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
From Alvotech
Via GlobeNewswire
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate Worth Considering ↗
Via Chartmill
News headline image
Dr. Reddy’s Q4 & Full Year FY25 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
How does DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) stack up against Peter Lynch’s investment principles? ↗
Via Chartmill
News headline image
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗
Via Benzinga
Topics Government Supply Chain World Trade
News headline image
Would Peter Lynch consider DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) a winning stock? ↗
Via Chartmill
News headline image
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire

Frequently Asked Questions

Is Dr. Reddy's Laboratories Ltd Common Stock publicly traded?
Yes, Dr. Reddy's Laboratories Ltd Common Stock is publicly traded.
What exchange does Dr. Reddy's Laboratories Ltd Common Stock trade on?
Dr. Reddy's Laboratories Ltd Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Dr. Reddy's Laboratories Ltd Common Stock?
The ticker symbol for Dr. Reddy's Laboratories Ltd Common Stock is RDY on the New York Stock Exchange
What is the current price of Dr. Reddy's Laboratories Ltd Common Stock?
The current price of Dr. Reddy's Laboratories Ltd Common Stock is 14.19
When was Dr. Reddy's Laboratories Ltd Common Stock last traded?
The last trade of Dr. Reddy's Laboratories Ltd Common Stock was at 12/05/25 07:00 PM ET
What is the market capitalization of Dr. Reddy's Laboratories Ltd Common Stock?
The market capitalization of Dr. Reddy's Laboratories Ltd Common Stock is 2.36B
How many shares of Dr. Reddy's Laboratories Ltd Common Stock are outstanding?
Dr. Reddy's Laboratories Ltd Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story